Tesamorelin Doses Used in Published Studies: What Researchers Reported

Tesamorelin is a synthetic analogue of growth hormone-releasing factor, and nearly all of its published clinical literature comes from one clinical context: adults living with HIV who had excess visceral abdominal fat. In those studies the amount administered was written into the protocol in advance, applied uniformly to every participant in the active arm, and monitored by investigators. This page describes what the published papers reported administering — the amount, the route, the schedule and the length of exposure — with each figure attached in the same sentence to the paper that reported it. It deliberately contains no dosing chart and no suggested amount, and it does not address product pricing or availability.

What a "studied dose" actually is

A dose that appears in a journal article describes one thing only: what the investigators gave, to a defined group of people, under supervision, for a defined period, while measuring defined endpoints. It carries the population with it. It carries the exclusion criteria with it. It carries the laboratory monitoring, the injection technique training and the stopping rules with it. Detached from all of that, a number is just a number. Researchers choose amounts to test a hypothesis efficiently and safely within a trial, not to produce a general-purpose instruction.

That distinction matters especially for a growth hormone-releasing factor analogue, because the pharmacology involves stimulating an endogenous axis whose output was measured in the trials. A population pharmacokinetic and pharmacodynamic analysis pooled data from healthy subjects and HIV-infected patients receiving subcutaneous tesamorelin and modelled the relationship between drug exposure and insulin-like growth factor 1 response (PMID 25895899). The fact that exposure-response modelling was necessary at all is a reminder that the same administered amount does not produce the same biological signal in every person.

The regimen described across the development programme

Independent drug reviews of tesamorelin consistently described a single fixed daily amount rather than a titration range. The 2011 review in Drugs described tesamorelin as being given at 2 mg by subcutaneous injection once daily in the trials that supported its use for HIV-associated lipodystrophy (PMID 21668043). A 2012 review in The Annals of Pharmacotherapy likewise described the growth hormone-releasing factor analogue as administered subcutaneously at 2 mg once daily in the HIV-associated lipodystrophy studies it summarised (PMID 22298602). A 2009 review in Expert Opinion on Investigational Drugs covered the same human growth hormone-releasing factor analogue and its once-daily subcutaneous administration in HIV-infected patients with abdominal fat accumulation (PMID 19243281), and a 2006 drug evaluation described the synthetic growth hormone-releasing factor at an earlier stage of clinical development, before the later phase III programme (PMID 17086939).

Two structural features of that programme are worth noting. First, the route was subcutaneous injection in every published clinical report cited here, not oral and not intramuscular. Second, the pivotal studies were measured in months. The 2011 review described the core randomised phase of the registration trials as running 26 weeks, with an extension phase that carried exposure to 52 weeks in participants who continued (PMID 21668043), and the 2012 review described the same 26-week randomised design followed by a 26-week extension (PMID 22298602).

Study by study: who was studied, for how long, and what was measured

Body composition, liver fat and metabolic endpoints

A 2026 meta-analysis of randomised controlled trials pooled tesamorelin studies in HIV-associated lipodystrophy and reported body composition, hepatic fat, metabolic and safety outcomes across those trials (PMID 41545261). Because it aggregated trials that used the programme's fixed subcutaneous daily regimen, it describes the average effect of that regimen rather than the effect of any individually chosen amount.

A pooled analysis published in AIDS in 2017 examined participants in the phase III tesamorelin trials and reported that reduction in visceral adipose tissue was associated with improvement in liver enzymes in people with HIV (PMID 28832410). The association was with the degree of visceral fat change, not with the administered amount, which was identical across the active arm.

Inflammatory and molecular endpoints

A 2011 study in AIDS examined inflammatory markers in HIV-infected patients with excess abdominal fat who received tesamorelin, and researchers reported that changes in those markers related to the extent of visceral adipose reduction (PMID 21516030). A 2021 report in Scientific Reports used a targeted proteomic and transcriptomic approach to delineate tesamorelin response pathways in HIV-associated non-alcoholic fatty liver disease, distinguishing participants whose liver fat responded from those whose did not (PMID 34006921). That second paper is a useful corrective to chart thinking: within a single fixed regimen, the study still found responders and non-responders.

Subgroups and newer questions

A 2024 analysis in AIDS examined the efficacy and safety of tesamorelin specifically in people with HIV taking integrase strand transfer inhibitors, a population in which weight gain has become a clinical concern (PMID 38905488). A 2025 randomised trial published in The Journal of Infectious Diseases assessed the effects of tesamorelin on neurocognitive impairment in persons with HIV and abdominal obesity, extending the outcome set beyond body composition to cognition (PMID 39813152). A 2026 protocol paper in BMJ Open described the TRIUMPH clinical trial, which was designed to test tesamorelin as an adjunct to exercise for improving physical function in people with HIV (PMID 42419889); as a protocol, it describes planned methods and not results.

What about animal data?

The verified literature summarised on this page is human clinical and review literature. No preclinical rodent dosing study is included here, so no animal amounts, no milligram-per-kilogram figures and no interspecies conversions are described. Where a reader encounters an animal-derived number presented as though it applied to people, the relevant question is whether the source paper actually studied the species and endpoint being claimed.

Adverse Events in Tesamorelin Studies: What Studies Report

Safety was a reported endpoint in this literature, not an afterthought. The 2026 meta-analysis of randomised controlled trials in HIV-associated lipodystrophy explicitly included safety outcomes alongside body composition, hepatic fat and metabolic results (PMID 41545261). The 2011 Drugs review summarised tolerability in the registration programme, describing injection-site reactions and musculoskeletal complaints among the adverse events recorded with subcutaneous tesamorelin (PMID 21668043), and the 2012 review in The Annals of Pharmacotherapy likewise discussed tolerability and glucose-related monitoring considerations for the growth hormone-releasing factor analogue (PMID 22298602). The 2024 AIDS analysis reported safety as well as efficacy in participants receiving integrase inhibitors (PMID 38905488).

Two points follow from how those safety data were generated. Adverse events were captured in supervised trials with eligibility screening and scheduled laboratory testing, so they describe what happened under monitoring. And because a growth hormone-releasing factor analogue acts on an endogenous hormonal axis, exposure-response modelling of insulin-like growth factor 1 was part of the published characterisation of the compound (PMID 25895899) — a signal that trial investigators tracked rather than assumed.

Why published study doses do not convert into a recommendation

• The population was narrow. The regimens described above were tested in adults living with HIV who had excess abdominal fat or HIV-associated lipodystrophy, as the 2011 and 2012 reviews both make clear (PMID 21668043, PMID 22298602). Findings in that population do not automatically describe anyone outside it.
• The amount was fixed, not titrated. Because the trials used one protocol-defined subcutaneous daily amount, the published data cannot say what a different amount would have done, and the 2021 pathway analysis showed that response still varied between individuals at the same regimen (PMID 34006921).
• Monitoring was part of the intervention. Laboratory follow-up, including growth-axis and metabolic measures, accompanied administration in this literature (PMID 25895899, PMID 41545261).
• Duration was bounded. The pivotal randomised phase ran 26 weeks with an extension to 52 weeks (PMID 21668043); the literature does not describe indefinite exposure.
• Endpoints were specific. Visceral fat, liver fat, liver enzymes, inflammatory markers, cognition and physical function were each studied separately (PMID 28832410, PMID 39813152, PMID 42419889), and a result on one endpoint is not a result on another.

Regulatory context

Tesamorelin has an approved prescription form, and the reviews cited here were written around its regulatory evaluation for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy (PMID 21668043, PMID 22298602). Material sold under the same chemical name in research-use-only channels is not the approved product, is not subject to the same manufacturing and labelling requirements, and has not been evaluated in the trials described above. Identity, purity and concentration of such material are not established by the published clinical literature.

What remains unsettled

Several open questions are visible in this literature. Whether metabolic and hepatic changes translate into differences in longer-term clinical outcomes was not answered by the 26-week registration design (PMID 21668043). Whether the compound affects cognition in this population was the specific question of the 2025 randomised trial (PMID 39813152), and whether it adds to exercise for physical function is the question a 2026 protocol was designed to test, with results not yet reported in that paper (PMID 42419889). Why some participants' liver fat responded and others' did not remains a subject of mechanistic work (PMID 34006921).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition, medication or health decision. It summarises what published studies reported administering and measuring, and nothing here should be read as a suggested amount, schedule or course of action.

References

• Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity (The Journal of Infectious Diseases, 2025)
• Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials (Obesity Research & Clinical Practice, 2026)
• Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy (The Annals of Pharmacotherapy, 2012)
• Tesamorelin, a human growth hormone releasing factor analogue (Expert Opinion on Investigational Drugs, 2009)
• Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach (Scientific Reports, 2021)
• Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor (Current Opinion in Investigational Drugs, 2006)
• Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy (Drugs, 2011)
• Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV (AIDS, 2017)
• Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors (AIDS, 2024)
• Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects (Journal of Pharmacokinetics and Pharmacodynamics, 2015)
• Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction (AIDS, 2011)
• Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol (BMJ Open, 2026)